212 related articles for article (PubMed ID: 23406852)
1. [Targets of anti-hyperlipidemia drugs].
Li H; Jing X; Deng X; Ouyang D
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Jan; 38(1):101-8. PubMed ID: 23406852
[TBL] [Abstract][Full Text] [Related]
2. Fucoidan A2 from the Brown Seaweed Ascophyllum nodosum Lowers Lipid by Improving Reverse Cholesterol Transport in C57BL/6J Mice Fed a High-Fat Diet.
Yang Z; Liu G; Wang Y; Yin J; Wang J; Xia B; Li T; Yang X; Hou P; Hu S; Song W; Guo S
J Agric Food Chem; 2019 May; 67(20):5782-5791. PubMed ID: 31055921
[TBL] [Abstract][Full Text] [Related]
3. Pharmacotherapy for dyslipidaemia--current therapies and future agents.
Bays H; Stein EA
Expert Opin Pharmacother; 2003 Nov; 4(11):1901-38. PubMed ID: 14596646
[TBL] [Abstract][Full Text] [Related]
4. Discovery Approaches for Novel Dyslipidemia Drugs.
Maqbool F; Safavi M; Bahadar H; Rahimifard M; Niaz K; Abdollahi M
Curr Drug Discov Technol; 2015; 12(2):90-116. PubMed ID: 26135857
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathways and agents for lowering LDL-cholesterol in addition to statins.
Costet P
Pharmacol Ther; 2010 Jun; 126(3):263-78. PubMed ID: 20227438
[TBL] [Abstract][Full Text] [Related]
6. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
7. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Brief Overview.
Noel ZR; Beavers CJ
Am J Med; 2017 Feb; 130(2):229.e1-229.e4. PubMed ID: 27751895
[TBL] [Abstract][Full Text] [Related]
8. Emerging drugs for hyperlipidemia.
Paras C; Hussain MM; Rosenson RS
Expert Opin Emerg Drugs; 2010 Sep; 15(3):433-51. PubMed ID: 20423271
[TBL] [Abstract][Full Text] [Related]
9. Antihyperlipidemic therapies targeting PCSK9.
Weinreich M; Frishman WH
Cardiol Rev; 2014; 22(3):140-6. PubMed ID: 24407047
[TBL] [Abstract][Full Text] [Related]
10. A study on cholesterol-cholesteryl ester metabolic homeostasis and drug intervention in hyperlipidemic hamsters using UHPLC-MS/MS.
Wang Z; Wang Z; Lin M; Zheng B; Zhang J
J Pharm Biomed Anal; 2024 Mar; 240():115933. PubMed ID: 38154368
[TBL] [Abstract][Full Text] [Related]
11. Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables.
Filippatos TD; Kei A; Rizos CV; Elisaf MS
J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):3-12. PubMed ID: 28826253
[TBL] [Abstract][Full Text] [Related]
12. The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies.
Lambert G; Thedrez A; Croyal M; Ramin-Mangata S; Couret D; Diotel N; Nobécourt-Dupuy E; Krempf M; LeBail JC; Poirier B; Blankenstein J; Villard EF; Guillot E
Clin Sci (Lond); 2017 Feb; 131(4):261-268. PubMed ID: 28108631
[TBL] [Abstract][Full Text] [Related]
13. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
[TBL] [Abstract][Full Text] [Related]
14. Novel strategies for managing dyslipidemia: treatment beyond statins.
Ling H; Burns TL; Hilleman DE
Postgrad Med; 2012 Nov; 124(6):43-54. PubMed ID: 23322138
[TBL] [Abstract][Full Text] [Related]
15. Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy.
Gaudet D; Drouin-Chartier JP; Couture P
Can J Cardiol; 2017 Jul; 33(7):872-882. PubMed ID: 28365054
[TBL] [Abstract][Full Text] [Related]
16. Novel pharmacotherapies of familial hyperlipidemia.
Drakopoulou M; Toutouzas K; Stefanadis C
Pharmacol Ther; 2013 Sep; 139(3):301-12. PubMed ID: 23639874
[TBL] [Abstract][Full Text] [Related]
17. HVC1 ameliorates hyperlipidemia and inflammation in LDLR
Cheon SY; Chung KS; Lee KJ; Choi HY; Ham IH; Jung DH; Cha YY; An HJ
BMC Complement Altern Med; 2017 Apr; 17(1):222. PubMed ID: 28427397
[TBL] [Abstract][Full Text] [Related]
18. Hypolipidemic effect of SIPI-7623, a derivative of an extract from oriental wormwood, through farnesoid X receptor antagonism.
Deng YF; Huang XL; Su M; Yu PX; Zhang Z; Liu QH; Wang GP; Liu MY
Chin J Nat Med; 2018 Aug; 16(8):572-579. PubMed ID: 30197122
[TBL] [Abstract][Full Text] [Related]
19. Beneficial effects of mangiferin on hyperlipidemia in high-fat-fed hamsters.
Guo F; Huang C; Liao X; Wang Y; He Y; Feng R; Li Y; Sun C
Mol Nutr Food Res; 2011 Dec; 55(12):1809-18. PubMed ID: 22038976
[TBL] [Abstract][Full Text] [Related]
20. [MTP inhibitors and ACAT inhibitors. An update].
Ohashi K
Nihon Rinsho; 2002 May; 60(5):975-83. PubMed ID: 12030002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
